

PRODUCT MONOGRAPH

ENTERIC COATED ASA[®]

(Acetylsalicylic Acid)

Tablets/Caplets, 325 and 650 mg

**Nonsteroidal Anti-inflammatory, Analgesic Agent
Platelet Aggregation Inhibitor**

**PENDOPHARM INC.
8580 Esplanade
Montréal, Canada
H2P 2R8**

**Date of Preparation:
February 03, 2005**

Control No.: 096692

PRODUCT MONOGRAPH

ENTERIC COATED ASA® Tablets

Nonsteroidal Anti-inflammatory Analgesic Agent Platelet Aggregation Inhibitor

ACTION AND CLINICAL PHARMACOLOGY

Enteric Coated ASA (acetylsalicylic acid) has analgesic, antipyretic and anti-inflammatory properties.

In rheumatic diseases, although the analgesic and antipyretic effects are useful, the major purpose for which ASA is used is to reduce the intensity of the inflammatory process. Inhibition of prostaglandin synthesis may be involved in the anti-inflammatory action of ASA.

ASA also alters platelet aggregation and release reaction by inhibiting prostaglandin synthesis. Thromboxane A₂ is an essential step in platelet aggregation. ASA prevents Thromboxane A₂ formation by acetylation of platelet cyclooxygenase. This inhibition of prostaglandin synthesis is irreversible and affects platelet function for the life of the platelet.

The enteric coating substantially resists disintegration in aqueous fluids having a pH lower than 3.5 for a period of at least 2 hours and is capable of disintegrating in aqueous fluids having a pH of at least 5.5 in from 10 to 30 minutes. Thus, enteric coating effectively inhibits the release of ASA in the stomach, while allowing the tablet to dissolve in the upper portion of the small intestine for absorption from the duodenal area.

Clinical experience has shown that enteric-coated acetylsalicylic acid diminishes or eliminates gastric distress during long-term treatment with high doses of ASA.

Pharmacokinetic Information

Since ENTERIC COATED ASA[®] tablets are enteric-coated, the pharmacological effects are not immediate. Peak serum salicylate concentrations are reached 6 to 8 hours after single oral administration. This means that ENTERIC COATED ASA[®] tablets are more useful for chronic administration as in arthritis, than for providing prompt relief of pain and fever.

The plasma half-life of salicylate concentrations is dose-dependent being 3 to 6 hours at low doses (325 mg to 1.3 g) and 15 to 30 hours at high doses.

INDICATIONS AND CLINICAL USE

ENTERIC COATED ASA[®] is indicated whenever gastric intolerance to ASA is of concern.

ENTERIC COATED ASA[®] is indicated for the relief of signs and symptoms of the following::

Osteoarthritis

Rheumatoid arthritis

Spondylitis Bursitis and other forms of rheumatism

Musculoskeletal disorders

Rheumatic fever, however, penicillin and other appropriate therapy should be administered concomitantly.

ASA is generally considered to be the primary therapy for most forms of arthritis.

Based on its platelet aggregation inhibitory properties, ENTERIC COATED ASA[®] is indicated for the following:

- for reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction
- for reducing the risk of recurrent transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction,

CONTRAINDICATIONS

Sensitivity to the ingredients; active peptic ulcer. Patients who had a broncho spastic reaction to ASA or non-steroidal anti-inflammatory drugs.

WARNINGS

ASA is one of the most frequent causes of accidental poisoning in toddlers and infants. ENTERIC COATED ASA® should, therefore, be kept well out of the reach of all children.

PRECAUTIONS

Salicylates should be administered with caution to patients with asthma and other allergic conditions, with a history of gastrointestinal ulcerations, with bleeding tendencies, with significant anemia or with hypoprothrombinemia.

Salicylates can produce changes in thyroid function tests.

Acute hepatitis has been reported rarely in patients with systemic lupus erythematosus and juvenile rheumatoid arthritis with plasma salicylate concentrations above 25 mg/100 mL. Patients have recovered upon cessation of therapy.

Regular daily use of alcohol while on ASA daily therapy may increase the risk of gastrointestinal bleeding.

Use in Pregnancy

ASA does not appear to have any teratogenic effects. ASA has been found to delay parturition in rats. This effect has also been described with non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis.

High doses (3 g daily) of ASA during pregnancy may lengthen the gestation and parturition time. Because of possible adverse effects on the neonate and the potential for increased maternal blood loss, ASA should be avoided during the last three months of pregnancy.

Use in Children

Recent studies have suggested that acetylsalicylic acid usage may cause the development of Reye's syndrome in children and teenagers with acute febrile illnesses, especially influenza and varicella. Although a direct causal relationship has not been established, it is recommended that salicylates be avoided when possible in children and teenagers with influenza or varicella.

Drug Interactions

Caution is necessary when ENTERIC COATED ASA[®] and anticoagulants are prescribed concurrently, as ASA can depress the concentration of prothrombin in the plasma and may potentiate the action of anticoagulants.

Salicylates may potentiate sulfonylurea hypoglycemic agents. Large doses of salicylates may have a hypoglycemic action, and thus, affect the insulin requirements of diabetics.

Although salicylates in large doses are uricosuric agents, smaller amounts may depress uric acid clearance and thus decrease the uricosuric effects of probenecid, sulfipyrazone and phenylbutazone.

Sodium excretion produced by spironolactone may be decreased in the presence of salicylates.

Salicylates also retard the renal elimination of methotrexate.

Salicylates may alter valproic acid (VPA) metabolism and displace VPA from protein binding sites, possibly intensifying the effects of VPA. Caution is recommended when VPA is administered concomitantly with salicylates.

ADVERSE REACTIONS

Gastrointestinal: nausea, vomiting, diarrhea, gastrointestinal bleeding and/or ulceration.

Ear: tinnitus, vertigo, hearing loss.

Hematologic: leukopenia, thrombocytopenia, purpura, anemia.

Dermatologic and

Hypersensitivity: urticaria, angioedema, pruritus, various skin eruptions, asthma and anaphylaxis.

Miscellaneous: acute reversible hepatotoxicity, mental confusion, drowsiness, sweating and thirst.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Symptoms

In mild overdosage these may include rapid and deep breathing, nausea, vomiting (leading to alkalosis), hyperpnea, vertigo, tinnitus, flushing, sweating, thirst and tachycardia. (High blood levels of ASA lead to acid-base disturbances including respiratory alkalosis and metabolic acidosis.) Severe cases may show fever, hemorrhage, excitement, confusion, convulsions or coma, and respiratory failure.

Treatment

Treatment is essentially symptomatic and supportive. Administer water, universal antidote and remove by gastric lavage or emesis. Force fluids (e.g., salty broth) to replace sodium loss. If the patient is unable to retain fluids orally, the alkalosis can be treated by hypertonic saline intravenously. If salicylism acidosis is present, sodium bicarbonate intravenously is preferred because it increases the renal excretion of salicylates. Vitamin K is indicated if there is evidence of hemorrhage. Hemodialysis has been used with success.

Respiratory depression may require artificial ventilation with oxygen. Convulsions may best be treated by the administration of succinylcholine and artificial ventilation with oxygen. Central nervous system depressant agents should not be used.

Hyperthermia and dehydration are immediate threats to life and initial therapy must be directed to their correction and to the maintenance of adequate renal function. External cooling with cool water or alcohol should be provided quickly to any child who has a rectal temperature over 40°C.

DOSAGE AND ADMINISTRATION

Dosage Adults: Single dose should not exceed 650 mg, to be repeated every 4 to 6 hours; the total daily dosage should not exceed 4,000 mg ASA unless otherwise advised by a physician, i.e, 12 tablets 325 mg or 6 tablets 650 mg.

If the underlying condition requires continued use of ENTERIC COATED ASA[®] for more than 5 days, a physician should be consulted.

Children: only as directed by a physician.

Analgesic; Antipyretic

Patients should be advised not to exceed 4.0 g daily. Single doses should not be administered more frequently than every 4 hours.

Anti-inflammatory

Because the suppression of inflammation increases with the dose of salicylate even beyond the point of toxicity, the therapeutic objective is to employ as large a dose as possible short of toxicity. Most patients will tolerate blood salicylate levels in the range of 20 to 25 mg per cent. The most common reason for failing to obtain a therapeutic response to ASA is the administration of inadequate doses.

The generally accepted way to achieve effective anti-inflammatory salicylate blood levels of 20 to 25 mg per cent is to titrate the dosage by starting with 2.6 to 3.9 g daily, according to the size, age and sex of the patient. If necessary, the dosage is then gradually adjusted by daily increments of 0.65 g. Optimally, salicylate therapy should be monitored by periodic blood salicylate level determinations. If this is not practical, the appearance of auditory symptoms in the form of tinnitus or deafness are acceptable as an indication of the maximum tolerated salicylate dose.

In adults, the median dose at which tinnitus develops is 4.5 g per day, but the range extends from 2.6 to 6.0 g per day.

Intermittent administration is ineffective. Patients should be advised not to vary the dose from day to day depending on the level of pain because that often, fluctuates independently of the intensity of the inflammation. A continuous regimen of 0.65 g four times daily is considered to be minimum therapy for adults. ENTERIC COATED ASA[®] should be administered four times daily. For night-time and early morning benefits, the last dose should be given at bedtime.

Once maintenance dose is established, ENTERIC COATED ASA[®] 15 Maximum Strength may be useful to encourage patient compliance.

There is an inverse relation between blood salicylate levels at which auditory symptoms appear and the age of the patient. In the young adult, this is usually in the range of 20 to 30 mg per cent. In children, however, the level may be much higher, or the effect apparently absent. Because salicylate toxicity may appear without such warning in children, the usual practice is to give ASA in a daily dose of 50 to 80 mg per kilogram of body weight and to follow blood levels aiming for a concentration of about 30 mg per cent.

Rheumatic Fever

A total daily dosage of 80 mg per kilogram of body weight administered in divided doses to allay the pain, swelling and fever.

Platelet Aggregation Inhibitor

Patients with unstable angina or previous myocardial infarction: 325 mg daily or every second day, depending on the individual needs of the patient as directed by a physician. Therapy to continue indefinitely.

Patients with recurrent transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction: 325 mg daily or every second day, depending on the individual needs of the patient as directed by a physician. Therapy to continue indefinitely.

PHARMACEUTICAL INFORMATION


Drug Substance

Trade Name: ENTERIC COATED ASA[®]

Common Name: Acetylsalicylic Acid (ASA)

Chemical Name: Salicylic acid acetate

Structural Formula of Acetylsalicylic Acid:



Molecular formula: C₉H₈O₄

Molecular weight: 180.16

AVAILABILITY OF DOSAGE FORMS

No. 47OX - ENTERIC COATED ASA[®] Super Extra Strength tablets contain 650 mg of acetylsalicylic acid, enteric-coated. Oval, orange, film-coated tablets printed ENTERIC COATED ASA[®] 650 mg in black on one side. Supplied in bottles of 100 (child-resistant package).

No. 48OX - ENTERIC COATED ASA[®] Super Extra Strength caplets contain 650 mg of acetylsalicylic acid, enteric-coated. Capsule-shaped, orange, film-coated caplets printed ENTERIC COATED ASA[®] 650 mg in black on one side. Supplied in bottles of 100 (child-resistant package).

No. 438 - ENTERIC COATED ASA[®] Regular Strength tablets contain 325 mg of acetylsalicylic acid, enteric-coated. Round, brown, film-coated tablets printed ENTERIC COATED ASA[®] 325 mg in black on one side. Supplied in bottles of 100 and 200 (child-resistant package).

No. 478 - ENTERIC COATED ASA[®] Regular Strength caplets contain 325 mg of acetylsalicylic acid, enteric-coated. Capsule-shaped, yellow, film-coated caplets printed ENTERIC COATED ASA[®] 325 mg in black on one side. Supplied in bottles of 100 and 200 (child-resistant package).

Following is the list of non-medicinal ingredients: carnauba wax, cellulose acetate phthalate, corn starch, diethyl phthalate, guar gum, hydrogenated vegetable oil, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, polyvinyl acetate phthalate, sodium lauryl sulfate, sucrose and coloring agents (black ferric oxide, red ferric oxide, sunset yellow aluminum lake, titanium dioxide).

Store at 15 - 30°C. Protect from moisture.

INFORMATION FOR THE PATIENT

ENTERIC COATED ASA®

Acetylsalicylic Acid Delayed-release Tablets USP

DESCRIPTION

WHAT ENTERIC COATED ASA® CONTAINS

ENTERIC COATED ASA® Coated Tablets and Caplets contain acetylsalicylic acid, also known as ASA.

WHAT ENTERIC COATED ASA® DOES

ENTERIC COATED ASA® Coated Tablets and Caplets have the following characteristics:

Action

ENTERIC COATED ASA® Coated Tablets and Caplets contain ASA. Clinical practice has established the suitability of ASA in relieving pain associated with conditions such as minor body aches, muscle, back and joint pain.

Special, enteric coating to help prevent stomach upset

The special enteric coating of ENTERIC COATED ASA® enables the tablet or caplets to pass, undissolved, through the acidic stomach and enter the upper portion of the small intestine, a less acidic environment. It is then that the tablet or caplet is dissolved, thus it is less likely to cause stomach irritation that is sometimes associated with plain or buffered ASA.

Onset of Action

Because ENTERIC COATED ASA[®] Coated Tablets and Caplets are specially coated to reduce the risk of stomach upset, the ASA is not absorbed by the stomach and the onset of action will be somewhat delayed.

WHEN TO TAKE ENTERIC COATED ASA[®]

ENTERIC COATED ASA[®] is indicated for the relief of minor aches and pains, including the pain of inflammation associated with arthritis and rheumatism. ENTERIC COATED ASA[®] may be used for backache, bursitis pain, knee pain, joint pain, muscle aches, lower back pain, tennis elbow. It is also useful in relieving pain and aches associated with colds.

HOW TO TAKE ENTERIC COATED ASA[®]

ADULTS

The tablets and caplets must be swallowed whole, with a large glass of water (250 mL); do not crush or break up. It is hazardous to exceed the maximum recommended dose (650 mg per single dose or 4 g daily) unless advised by your physician. Consult your physician if your condition does not improve after 5 days of continued product use.

PRECAUTIONS

If you are taking other medication, carefully read the labels to ensure that they do not also contain acetylsalicylic acid which could result in an overdose. If in doubt, consult your physician or pharmacist. If you expect to undergo surgery, including dental surgery within 5 to 7 days of taking ASA or ENTERIC COATED ASA[®] Coated Tablets or Caplets, consult your physician or pharmacist.

Consult a physician before taking this drug during the last three months of pregnancy or when breast-feeding.

DO NOT ADMINISTER ENTERIC COATED ASA[®] to children or teenagers who have chicken pox or flu symptoms before a physician or pharmacist is consulted about Reye's Syndrome, a rare and serious illness.

There is enough drug in each package to seriously harm a child.

Keep this medicine out of the reach of children.

WHEN TO CONSULT YOUR PHYSICIAN OR PHARMACIST ABOUT ENTERIC COATED ASA[®]

A physician or pharmacist should be consulted prior to taking this medication in case of:

- allergy to salicylates or asthma
- during pregnancy or when breast-feeding
- if you have stomach problems, peptic ulcer, severe liver disease or gout
a history of blood coagulation defects, or when receiving anticoagulant drugs
- ASA is not recommended 5 to 7 days prior to surgery or in the presence of severe anemia
- intake of other medications containing salicylates or acetaminophen, anti-inflammatory drugs, anticonvulsants, anti-diabetic or gout medicine.

POSSIBLE SIDE EFFECTS

ENTERIC COATED ASA® Coated Tablets and Caplets occasionally may produce some unwanted effects. A physician should be contacted if any of the following reactions develop during treatment:

- bleeding or irritation of stomach (nausea, vomiting, pain)
- any loss of hearing, including ringing or buzzing in the ears
- skin rashes, hives or itching
- breathing difficulties.

WHAT TO DO IN CASE OF OVERDOSE

IN CASE OF ACCIDENTAL OR SUSPECTED OVERDOSE, CONTACT A PHYSICIAN, A POISON CONTROL CENTRE, OR THE EMERGENCY DEPARTMENT OF A HOSPITAL IMMEDIATELY, EVEN IF THERE ARE NO SYMPTOMS.

The signs and symptoms of an overdose usually occur within a few hours after ingestion. They may include: stomach upset, convulsions (seizures), hearing loss, mental confusion, ringing or buzzing in the ears, severe drowsiness or tiredness, severe excitement or nervousness and unusually fast or deep breathing, hallucinations or changes in behaviour (especially in children).

DESCRIPTION

Enteric-coated tablets or caplets printed in black with product name and potency declared in mg per tablet or caplet.

REGULAR STRENGTH ENTERIC COATED ASA®	SUPER EXTRA STRENGTH ENTERIC COATED ASA®
325 mg tablets and caplets	650 mg tablets and caplets
<i>Usual dosage</i> 1-2 tablets or caplets every four hours	<i>Usual dosage</i> 1 tablet or caplet every four hours
Maximum daily dosage (4000 mg a day) 12 tablets/caplets	Maximum daily dosage (4000 mg a day) 6 tablets/caplets
For low dose ASA therapy. For relief of mild aches and pains due to muscle and joint strain.	For relief of moderate joint pain caused by arthritis and athletic injuries.

Product Monograph available to health professionals on request.

ENTERIC COATED ASA®

Acetylsalicylic Acid Delayed-Release Tablets 325 mg USP FOR LONG-TERM ASA PREVENTATIVE THERAPY

This leaflet gives you important information on Coated ENTERIC COATED ASA® and how to use it for Long-Term ASA Preventative Therapy. Please read carefully before using this medicine.

WHY DID MY DOCTOR RECOMMEND ENTERIC COATED ASA®

- Different than dosing regimens for conditions such as arthritis, your doctor recommended a lower dose ASA regimen of ENTERIC COATED ASA® for supervised adult long-term preventative therapy. Follow your doctor's instructions on how to take this medication. Contact your doctor if you have any questions about your therapy or your condition.
- Coated ENTERIC COATED ASA® has a special formulation of ASA (Acetylsalicylic Acid) recommended by your doctor for your condition.

HOW DOES THE SPECIALLY-FORMULATED ENTERIC COATED ASA® COATING WORK

- The special enteric coating of ENTERIC COATED ASA® enables the tablet or caplet to pass, undissolved, through the acidic stomach and enter the upper portion of the small intestine, a less acidic environment. It is then that the tablet or caplet is dissolved, thus it is less likely to cause stomach irritation that is sometimes associated with plain or buffered ASA.

HOW SHOULD I TAKE THIS MEDICATION

It is very important that you take this medicine as directed by your doctor. Do not take this medicine until you have seen your doctor.

Adult Dosage: 1 tablet (325 mg) daily or every second day, according to the individual needs of the patient as directed by a physician. Therapy to continue indefinitely under a doctor's supervision. The tablets and caplets must be swallowed whole, with a large glass of water (250 mL); do not crush or break up.

Follow your doctor's instructions on lifestyle changes, such as diet and exercise.

It is hazardous to exceed the maximum recommended dose unless advised by a physician.

ARE THERE SIDE EFFECTS WITH THIS MEDICINE

Like all medicines, ASA may occasionally produce some unwanted effects. A physician should be contacted if any of the following reactions develop during treatment:

- bleeding or irritation of stomach (nausea, vomiting, pain)
- any loss of hearing, including ringing or buzzing in the ears
- skin rashes, hives or itching a breathing difficulties.

WHAT ELSE SHOULD I KNOW BEFORE I TAKE THIS MEDICINE

Your doctor will have considered your specific condition before recommending a preventative therapy regimen of ENTERIC COATED ASA®. Therefore, it is important to keep your doctor informed of all details regarding your health, lifestyle and medications.

If you forgot to tell your doctor about any of the following, call your doctor or pharmacist before taking this medicine:

- allergy to salicylates or asthma
- during pregnancy or when breast-feeding
- if you have stomach problems, peptic ulcer, severe liver disease or gout
- a history of blood coagulation defects, or when receiving anticoagulant drugs
- ASA is not recommended 5 to 7 days prior to surgery or in the presence of severe anemia
- intake of other medications containing salicylates or acetaminophen, anti-inflammatory drugs, anticonvulsants, anti-diabetic or gout medicine.

WHAT SHOULD I DO IN CASE OF OVERDOSE

In case of accidental or suspected overdose, contact a physician, a poison control centre, or the emergency department of a hospital immediately, even if there are no symptoms.

The signs and symptoms of an overdose usually occur within a few hours after ingestion. They may include: stomach upset, convulsions (seizures), hearing loss, mental confusion, ringing or buzzing in the ears, severe drowsiness or tiredness, severe excitement or nervousness and unusually fast or deep breathing, hallucinations or changes in behaviour (especially in children).

IMPORTANT PRECAUTIONS

If you are taking other medication, carefully read the labels to ensure that they do not also contain acetylsalicylic acid which could result in an overdose. If in doubt, consult your physician or pharmacist. If you expect to undergo surgery, including dental surgery within 5 to 7 days of taking ASA or ENTERIC COATED ASA® Coated Tablets or Caplets, consult your physician or pharmacist.

Consult a physician before taking this drug during the last three months of pregnancy or when breast-feeding.

Regular daily use of alcohol while on ASA daily therapy may increase your risk of developing gastrointestinal bleeding.

DO NOT ADMINISTER ENTERIC COATED ASA® to children or teenagers who have chicken pox or flu symptoms before a physician or pharmacist is consulted about Reye's Syndrome, a rare and serious illness.

● **CAUTION: There is enough drug in each package to seriously harm a child. Keep this medicine out of the reach of children.**

ENTERIC COATED ASA® is available as a tablet or caplet.

Medicinal Ingredient: Acetylsalicylic Acid 325 mg

Product Monograph available to health professionals on request.

PHARMACOLOGY

The absorption of salicylates occurs predominantly by passive diffusion of undissociated drug molecules across gastrointestinal membranes (Schanker et al, 1958). ASA is rapidly hydrolyzed to salicylic acid. Salicylate is widely distributed throughout the body with highest concentrations found in the kidney, cortex, liver, heart, and lung. Brain concentrations are relatively low (Davidson et al, 1961). Salicylate metabolism differs in various species. Conjugation is relatively slow in men; however, it probably occurs in many tissues. The chief metabolic products in men are the conjugates with glycine (salicyluric acid) the ether or phenolic glucuronide (salicylic phenolic glucuronide), and the ester or acyl glucuronide (salicylic acyl glucuronide).

A small fraction is oxidized to gentisic and other hydroxybenzoic acids. Excretion of salicylates is almost entirely via the kidney. No salicylic compounds can be found in the urine or blood about 48 hours after the last dose (Milne, 1963), the excretion rate of free salicylate is highly variable and is dependent primarily on urinary pH; they are also influenced by glomerular filtration, proximal tubular secretion and urine flow rates. Urinary alkalinity increases the excretion of salicylate; small pH changes in alkaline urine may have a considerable effect, but pH changes in the acid range have little effect on the excretion rate. The excretion of salicylate conjugates is more affected by changes in glomerular filtration or proximal tubular secretion than by changes in urine flow or urine pH. However, urinary pH does affect the proportion excreted as metabolites. The mean free salicylate in human urine was found to be 61 % in studies using C14 labelled salicylate (Milne, 1963), in alkaline urine, up to 85%, whereas in acid urine, free salicylate may amount to only 10% of the ingested dose.

Thus, the amounts of metabolic products found in the urine have shown a wide range: salicyluric acid, 0 to 60% of the ingested dose (mean 8%); salicylic phenolic glucuronide, 12 to 30% (mean 22%); salicylic acyl glucuronide, 0 to 10% (mean 5%); and gentisic acid about 1%. The uricosuric action of salicylate has been confirmed repeatedly. However, at low dosage of salicylate, less than 2 g per day there is a paradoxical reversal of this action and urate is retained (Yu & Gutman, 1959). High doses, 5 to 8 g per day are required for consistent uricosuria. Salicylates exert inhibitory effect on at least 3 vital groups of cellular enzymes, those concerned with oxidative phosphorylation, the transaminases and the dehydrogenases, (Smith, 1963). Studies in vitro and in vivo have shown that salicylates depress the biosynthesis of mucopolysaccharide sulfates in representative connective tissues, cartilage, heart valves and cornea (Whitehouse, 1963).

Salicylates may reduce the blood sugar of both maturity onset and juvenile type diabetics, the fasting blood sugar being more affected than postprandial levels (Stowers, 1963).

At concentrations encountered clinically, from 50 to 90% of the salicylate is bound to plasma proteins, especially albumin. Hypoalbuminemia, as may occur in rheumatoid arthritis, is associated with a

proportionately higher level of free salicylate in the plasma. Salicylate stimulates respiration directly and indirectly. Full therapeutic doses of salicylates increase oxygen consumption and carbon dioxide production in experimental animals and men.

Established actions of ASA include suppression of antibody production, interference with antigen-antibody aggregation, inhibition of antigen-induced histamine release in vitro, and stabilization of capillary permeability in the presence of either immunological or non-immunological insults.

ASA inhibits platelet aggregation by irreversibly acetylating platelet cyclooxygenase thereby preventing the formation of thromboxane A₂ production. Maximal inhibition of thromboxane A₂ production and platelet aggregation can be obtained with ASA doses of 300 mg (Jakubowski, 1985). Enteric-coated ASA formulations are also effective at doses of 325 mg (Ceriatti, 1987). Recovery of platelet cyclooxygenase activity after a single dose of enteric coated ASA is delayed 48-72 hours (Jakubowski, 1985). Suppression of platelet thromboxane A₂ production has also been shown to persist for at least 48 hours after seven doses of enteric coated ASA 325 mg administered on alternate days (Stampfer, 1986). Platelet aggregation is believed to be an important element in unstable coronary artery disease. Several clinical trials have shown that ASA administered in doses of 325-1500 mg/day reduces the incidence of myocardial infarction and death in patients with unstable angina (Cairns, 1985; Lewis, 1983) or previous myocardial infarction (Bredin, 1980; Elwood, 1974).

TOXICOLOGY

ACUTE TOXICITY

On the basis of his own studies and analysis of the work of other investigators, Boyd concluded that the acute oral LD₅₀ of ASA in all species studies, including man, is on the order of 1 to 2 g/kg.

LD₅₀

(Abdernalden, 1935 - Khera, K.S. 1976 - Boyd, E.M. 1959 - Brossi, A. et al, 1965)

SPECIES	ROUTE	LD50 (mg/kg)
Mice	P.O.	700-1100
Rats	P.O.	800-2000
Rabbits	P.O.	1000-1800
Dogs	I.V.	681
Mice	I.P.	420

Symptoms produced in rats by doses in this range were inactivity, lack of alertness or curiosity, cataleptic tenseness, anorexia, diarrhea, nosebleed, hyperreflexia, and convulsive twitching. Deaths occurring within one day were due to tonic-clonic convulsions and respiratory failure.

The respiratory changes induced by salicylates are partly due to their metabolic influence on oxygen consumption and CO₂ production, and are also brought about through their effects on the central nervous system. Respiratory failure may be a cause of death in the rat, as in man.

Deaths on the second and third days were due to cardiovascular shock. Autopsy revealed gastro-enteritis, hepatitis, nephritis, pulmonary edema, and lesser changes in numerous tissues. Toxic symptoms in other species are similar.

The lowest lethal dose (LDL) of ASA reported in the literature is 104 mg/kg for a child.

CHRONIC TOXICITY

ASA in concentrations of 130, 625, or 1270 mg/kg/day (2 to 20 times the maximum tolerated clinical dose of 4 g daily) was administered in the diet of mice for prolonged periods. All dosages had a deleterious effect on mean survival time, number of young born, and number of young raised to weaning age, with the largest dose showing the strongest effects. (Wright, H.N., 1967)

Studies have demonstrated growth retardation in immature rats after chronic oral administration of sodium salicylate or sodium acetylsalicylate (Limbeck, G.A. et al, 1966) and nephrotoxic effects in adult rats after intra peritoneal administration of 400 mg/kg or more of sodium salicylate. (Robinson, M.J. et al, 1967)

The damaging effect of ASA on the gastric mucosa has been studied by many investigators, but the mechanism of action is still unknown.

REFERENCES

Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.

Breiddin, K., et al: The German-Austrian Aspirin Trial: A Comparison of Acetylsalicylic Acid, Placebo, and Phenprocoumarin in Secondary Prevention of Myocardial Infarction, *Circulation* 62 (6, Part II): V63-V72, Dec. 1980.

Cairns, J.A., et al: Aspirin, sulfinpyrazone, or both in unstable angina, *N Engl J Med*: 313 (22): 1369-1375, 1985.

Cerletti, C., et al: Pharmacokinetics of enteric-coated aspirin and inhibition of platelet - thromboxane A2 and vascular prostacyclin generation in humans, *Clin. Pharmacol. Ther.* 42:175-80, 1987.

Elwood, P.C., Sweetnam, P.M.: Aspirin and Secondary Mortality after Myocardial Infarction, *Lancet*, Dec. 22-29, 1313-1315, 1974.

Fallen, E.L., et al: Report of the Canadian Cardiovascular Society's Consensus Conference on the Management of the Postmyocardial Infarction Patient. *Can. Med. Assoc. J.*: 144: 1015-1025, 1991.

Jakubowski J.A., Stampfer M.J., Vaillancourt R., and Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. *Br. J. Haematology* 1985; 60:635-642.

Lewis, H.D., et al: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina, *N Engl J Med* 309: 396-403, 1983.

Stampfer M, Jakubowski J, Deykin D, et al. Effect of Alternate-Day Regular and Enteric-Coated Aspirin on Platelet Aggregation, Bleeding Time, and Thromboxane A2 Levels in Bleeding-Time Blood. *Am J Medicine*, 1986; 81:400-404.